TY - JOUR
T1 - Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases
AU - Pandey, Akhilesh
AU - Blagoev, Blagoy
AU - Kratchmarova, Irina
AU - Fernandez, Minerva
AU - Nielsen, Mogens
AU - Zakarias Kristiansen, Troels
AU - Ohara, Osamu
AU - Podtelejnikov, Alexandre V.
AU - Roche, Serge
AU - Lodish, Harvey F.
AU - Mann, Matthias
N1 - Funding Information:
Work at the Center for Experimental Bioinformatics is supported by a generous grant from the Danish National Research Foundation to the Center for Experimental Bioinformatics (CEBI) at the University of Southern Denmark. A Pandey is supported by a Howard Temin Award from the National Cancer Institute (KO1 CA75447) and by a travel award from the Plasmid Foundation, Roskilde, Denmark. We thank Drs Stuart Decker and Andrius Kazlauskas for providing constructs for EGFR and PDGFR respectively. We would also like to thank Dr Stéphane Richard for the Grb2 expression vector.
PY - 2002/11/14
Y1 - 2002/11/14
N2 - We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.
AB - We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.
KW - Bioinformatics
KW - Mass spectrometry
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=0037079239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037079239&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1205988
DO - 10.1038/sj.onc.1205988
M3 - Article
C2 - 12439753
AN - SCOPUS:0037079239
SN - 0950-9232
VL - 21
SP - 8029
EP - 8036
JO - Oncogene
JF - Oncogene
IS - 52
ER -